about
Concept and Implementation of a Single Source Information System in Nuclear Medicine for Myocardial Scintigraphy (SPECT-CT data)Multimodality molecular imaging--from target description to clinical studies.German disease management guidelines: surgical therapies for chronic heart failure.Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST.177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer.Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma.Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.177Lu-PSMA Radioligand Therapy for Prostate Cancer.The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.Intraoperative 3-D mapping of parathyroid adenoma using freehand SPECT.No significant difference in the prognostic value of the 5th and 7th editions of AJCC staging for differentiated thyroid cancer.Imaging of a paraganglioma on C-11 choline PET/CT.Myocardial perfusion imaging and coronary calcium scoring with a two-slice SPECT/CT system: can the attenuation map be calculated from the calcium scoring CT scan?Risk-profile and outcome of small papillary and follicular thyroid carcinomas (<or=1 cm).Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response.Subacute Stroke Mimicking Cerebral Metastasis in 68Ga-PSMA-HBED-CC PET/CT.[177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer].99mTc-MDP SPECT-CT and Ultrasound in the Diagnosis and Staging of Thyroid Metastasis From Osteosarcoma.Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion.18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics.Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.Contribution of PET/CT to prediction of outcome in children and young adults with rhabdomyosarcoma.Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate Cancer.External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use.Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid.PSMA Theranostics: Current Status and Future Directions.Therapy refractory coronary compression caused by a cardiac metastasis: The role of imagingMicrovascular dysfunction in nonfailing arrhythmogenic right ventricular cardiomyopathySubvalvular hypertrophic calcification of the mitral annulus: [(18)F]FDG-PET-CT, MRI, and echocardiography findingsConcept and implementation of a computer-based reminder system to increase completeness in clinical documentationBenefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy
P50
Q30619840-C8450BAA-F55F-4157-B24A-1D5C9EEBC97FQ37364495-6A51E078-FB21-49D1-ACB1-B6864EC5EE17Q37681376-DCC4107C-78A4-452B-8296-BFFADC997C23Q37706172-FFD1B2B1-9AA8-4207-BF97-D957B22C11EDQ38720855-62D2A734-EC7B-431F-AE77-1F07A8C375C5Q38772071-71B64DDA-B60B-4E63-8A5E-088B6D7AD4A5Q38861197-191110B5-DDC7-46DB-BFA1-48FA4F849E45Q38879864-C5041199-583C-454E-8B41-FD0AC13EAB36Q39405668-BBAC732B-3104-4CD7-BA10-6DCF3F9950B4Q40332155-54F4296B-CC9C-4D3D-BCB3-E71BF35BDFC6Q42424719-22FE7018-13E2-47F0-BF39-A56FD1039775Q43509605-0BF16CD7-AA6E-4CBF-B43B-4DB2F3BBAC94Q46057861-B57714C0-17AB-4B10-98A7-778731DD6F2BQ46734445-1B3C7C35-A610-4BCE-8853-E27B87949F75Q46826948-7CDE5D2B-C03E-4A77-8422-F73C3E1D1AF9Q47174885-29981884-B974-4240-B1F4-4C87B43CB7FBQ47603267-62F66C0E-6417-4BED-8558-4204495CBCBCQ47731005-C164B48F-24C1-41A8-B6A0-E788725FA1BEQ48194472-F8A5FF6C-9B16-4F1A-AD60-2F221F9B2D8EQ48257941-D6D42B00-2FEB-44D8-8BAD-54CA621DA005Q48323017-3A996C0B-033F-4A56-A70C-08F7DA4EA715Q48650309-23D08346-9E6E-46EA-8B4E-04A83A04F19FQ49546570-B0248DA5-E0DB-49A8-A658-FB2D13E544CAQ49712753-DCD79288-BDFA-45AA-A167-2D01AB1ED949Q49992971-1AA02CF4-BDA0-4551-8607-03B1D22D742FQ52654885-94F9039E-7315-459A-9C16-85078E11DC34Q52948528-F66FA392-D4DE-4B14-83E9-CCC6D094B52AQ53203584-8C9D7C6D-08D6-416A-A893-D27E7AA4ED35Q53208631-0516FE59-EEAF-485C-8799-029AC007F085Q53695831-B5E109D0-137A-48A1-AAD7-C6F1A614695CQ53779588-DC69454D-BEFB-468C-9A8B-7CFB5CD825E8Q53790732-3D5A51A3-FA28-4EF4-A59B-15B5A802859DQ54071581-D3E84BF4-4C8C-4E4D-8DD2-E91C3FFDD0A6Q54957323-509A5B92-C56F-434B-B453-951998B3AB53Q55023828-D438ED26-AE76-48B0-9743-39992D92AE23Q82335824-61770F24-ADB2-4754-A5A7-5F2F2DF16D1EQ82662379-129EFFE6-279D-48A2-AB80-8AE43DDBF163Q83387775-A75FF52A-C2BB-4028-9A39-707DAFA49AE6Q83630777-2ADD6A23-3B53-44C1-A473-180E9BA51CCEQ88569919-30EEB58E-A331-4B11-A5E4-8197BD873992
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kambiz Rahbar
@ast
Kambiz Rahbar
@en
Kambiz Rahbar
@es
Kambiz Rahbar
@nl
Kambiz Rahbar
@sl
type
label
Kambiz Rahbar
@ast
Kambiz Rahbar
@en
Kambiz Rahbar
@es
Kambiz Rahbar
@nl
Kambiz Rahbar
@sl
prefLabel
Kambiz Rahbar
@ast
Kambiz Rahbar
@en
Kambiz Rahbar
@es
Kambiz Rahbar
@nl
Kambiz Rahbar
@sl
P214
P106
P214
P31
P496
0000-0002-4591-4055
P7859
viaf-62689192